Drug news
Phase II success for GSK 961081(GSK/Theravance) for COPD
GSK and Theravance announced positive data from a Phase II study of the dual acting muscarinic antagonist and beta 2 agonist (MABA) GSK 961081 as a treatment for moderate to severe COPD. The trial of 436 subjects showed clinically significant improvements to placebo for FEV1 trough on day 29, the primary endpoint.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins